When it comes to cancer research, Dr. Clay Siegall is one of the most publicized names. This magnificent man has saved many lives, and he will continue to do so for as long as possible. Siegall has a passion for the work that he specializes in. The guy has up to 15 patents, and he has written over 70 publications. In addition to that, Siegall is the chief executive officer at Seattle Genetics. This company specializes in developing and commercializing antibody-based therapies. Located in Bothell, Washington, this biotech-oncology company has close to 1,000 employees, and it’s one of the top job producers in the Puget Sound area.
Seattle Genetics is powered via rigorous research and scientific innovation. These are two very strong principles that the company stands-by to the highest degree. ADCETRIS, the company’s flagship drug, has earned over $350 million to date. ADCETRIS falls under the category of being an antibody-based therapy. Yes, these names can be a bit confusing, but they are some of the very best cancer fighting medications of all-time. This flagship drug is now being used all over the globe in up to 70 countries. Yes, this drug is reaching the masses thanks to Siegall’s business-savvy sense. Siegal has been able to enter the drug into multiple strategic-licensing deals with GlaxoSmithKlien, with Genetech, with Bayer, and with Pfizer. It is one of the best-selling cancer fighting drugs in history.
Siegall states that the company has over 20 new drugs in its pipeline. These new drugs are looking to be released in the future. As of today, Seattle Genetics’ stock has tripled in just five short years. That’s right! In the end, these advanced medications are designed to save lives and anything else is truly unacceptable. Dr. Clay Siegall just so happens to be the captain, and he will continue to steer this ship to even more success.